Underused Next-Generation Sequence Testing Revealed in MYLUNG Consortium Study
June 15th 2021Results from the first phase of the broad, collaborative MYLUNG research study in lung cancer provide a close-up look at current biomarker testing rates and turnaround times for patients treated in community practices within The US Oncology Network.
How to Leverage Real-World Data as COVID-19 Transforms Clinical Trials
October 27th 2020Due to efforts to reduce exposure to the coronavirus, oncology patient volumes initially decreased, treatment regimens were disrupted or altered, and new cancer diagnoses also slowed. This affected not only patient care, but also clinical trials.
Optimizing Benefit in Targeted Therapies Requires Multipronged Educational Approach
October 25th 2020Much is still unknown about the cancer process and how targeted therapies work on specific tumor vulnerabilities. Providers must closely follow evolving information, especially regarding adverse events.